Zacks Investment Research upgraded shares of Trevena (NASDAQ:TRVN) from a hold rating to a buy rating in a research note published on Friday morning. The brokerage currently has $1.75 target price on the biopharmaceutical company’s stock.

According to Zacks, “Trevena, Inc. is a biopharmaceutical company. It focuses on discovering and developing therapeutics for G protein coupled receptors. The Company’s product pipeline includes TRV027, TRV130, TRV734 and Delta opioid biased ligand which are in different clinical phases. Trevena, Inc. is based in King of Prussia, Pennsylvania. “

Several other analysts also recently commented on the company. HC Wainwright reissued a buy rating and issued a $7.00 price objective on shares of Trevena in a research note on Monday, August 13th. ValuEngine raised Trevena from a sell rating to a hold rating in a research note on Saturday, June 2nd. Cowen reissued a buy rating and issued a $10.00 price objective on shares of Trevena in a research note on Monday, May 7th. Finally, Oppenheimer set a $5.00 price target on Trevena and gave the company a buy rating in a research report on Thursday, May 3rd. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Trevena has a consensus rating of Buy and a consensus price target of $5.54.

Shares of Trevena stock traded down $0.04 on Friday, hitting $1.57. The company had a trading volume of 753,664 shares, compared to its average volume of 976,841. The company has a market cap of $124.01 million, a PE ratio of -1.30 and a beta of -0.45. Trevena has a 1 year low of $1.34 and a 1 year high of $2.88. The company has a quick ratio of 3.40, a current ratio of 3.40 and a debt-to-equity ratio of 0.28.

Trevena (NASDAQ:TRVN) last issued its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($0.13) EPS for the quarter, hitting the consensus estimate of ($0.13). The company had revenue of $2.50 million during the quarter, compared to analysts’ expectations of $5.50 million. research analysts anticipate that Trevena will post -0.67 EPS for the current year.

Several institutional investors and hedge funds have recently modified their holdings of TRVN. FMR LLC increased its position in shares of Trevena by 24.0% during the second quarter. FMR LLC now owns 5,288,100 shares of the biopharmaceutical company’s stock valued at $7,615,000 after acquiring an additional 1,022,830 shares during the last quarter. Millennium Management LLC increased its position in shares of Trevena by 112.3% during the second quarter. Millennium Management LLC now owns 1,005,820 shares of the biopharmaceutical company’s stock valued at $1,448,000 after acquiring an additional 532,129 shares during the last quarter. Renaissance Technologies LLC increased its position in shares of Trevena by 264.1% during the second quarter. Renaissance Technologies LLC now owns 521,700 shares of the biopharmaceutical company’s stock valued at $751,000 after acquiring an additional 378,400 shares during the last quarter. Paloma Partners Management Co purchased a new stake in shares of Trevena during the second quarter valued at approximately $411,000. Finally, GSA Capital Partners LLP increased its position in shares of Trevena by 186.2% during the second quarter. GSA Capital Partners LLP now owns 351,847 shares of the biopharmaceutical company’s stock valued at $507,000 after acquiring an additional 228,900 shares during the last quarter. 43.40% of the stock is owned by institutional investors.

About Trevena

Trevena, Inc, a biopharmaceutical company, develops therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. Its product candidates include OLINVO injection, a G protein biased ligand of the µ opioid receptor that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is preferred; TRV250, a G protein biased ligand targeting the d-receptor, which is in Phase I clinical study for the treatment of migraine; and TRV734, a small molecule G protein biased ligand of the µ opioid receptor that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain, as well as TRV027 for the treatment of acute heart failure.

Featured Article: What do investors mean by earnings per share?

Get a free copy of the Zacks research report on Trevena (TRVN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Trevena (NASDAQ:TRVN)

Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.